UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 68

Sortiert nach

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study

Journal of clinical oncology, 2012-03, Vol.30 (7), p.709-717

2012

Volltextzugriff (PDF)

Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines

Journal of clinical oncology, 2006-06, Vol.24 (16), p.2444-2447

2006

Volltextzugriff (PDF)

Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer

Journal of clinical oncology, 2005-08, Vol.23 (22), p.5126-5137

2005

Volltextzugriff (PDF)

Impact of aromatase inhibitors on bone health in breast cancer patients

Journal of steroid biochemistry and molecular biology, 2010-02, Vol.118 (4), p.294-299

2010

Volltextzugriff (PDF)

Recent data on intratumor estrogens in breast cancer

Steroids, 2011-07, Vol.76 (8), p.786-791

2011

Volltextzugriff (PDF)

Alterations in the p53 Pathway and p16INK4a Expression Predict Overall Survival in Metastatic Melanoma Patients Treated with Dacarbazine

Journal of investigative dermatology, 2010-10, Vol.130 (10), p.2514-2516

2010

Volltextzugriff (PDF)

Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression

Journal of steroid biochemistry and molecular biology, 2008-02, Vol.108 (3), p.196-202

2008

Volltextzugriff (PDF)

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

The New England journal of medicine, 2004-03, Vol.350 (11), p.1081-1092

2004

Volltextzugriff (PDF)

Molecular portraits of human breast tumours

Nature (London), 2000-08, Vol.406 (6797), p.747-752

2000

Volltextzugriff (PDF)

SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer

European journal of cancer (1990), 2012-09, Vol.48 (13), p.1988-1996

2012

Volltextzugriff (PDF)

Aromatase inhibitors—Socioeconomical issues

Journal of steroid biochemistry and molecular biology, 2007-08, Vol.106 (1), p.55-61

2007

Volltextzugriff (PDF)

Mutation of GATA3 in human breast tumors

Oncogene, 2004-10, Vol.23 (46), p.7669-7678

2004

Volltextzugriff (PDF)

Clinical pharmacokinetics of aromatase inhibitors and inactivators

Clinical pharmacokinetics, 2003-01, Vol.42 (7), p.619-631

Lonning, Per E

2003

Volltextzugriff (PDF)

High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy

Breast cancer research and treatment, 2001-05, Vol.67 (2), p.111-116

2001

Volltextzugriff (PDF)

Aromatase inhibitors as adjuvant treatment of breast cancer

Critical reviews in oncology/hematology, 2006, Vol.57 (1), p.53-61

2006

Volltextzugriff (PDF)

Breast cancer prognostication and prediction: are we making progress?

Annals of oncology, 2007-09, Vol.18 (suppl-8), p.viii3-viii7

Lønning, P. E

2007

Volltextzugriff (PDF)

Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer

Breast cancer research and treatment, 1998-01, Vol.49 (S1), p.S45-S52

LØNNING, P. E

1998

Volltextzugriff (PDF)

Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique

Cancer Immunology, Immunotherapy, 2006-10, Vol.55 (10), p.1280-1284

2006

Volltextzugriff (PDF)

Aromatase inhibitors—Socio-economical issues

Journal of steroid biochemistry and molecular biology, 2005-05, Vol.95 (1), p.137-142

2005

Volltextzugriff (PDF)

Aromatase inhibitors and inactivators for breast cancer therapy

Drugs & aging, 2002, Vol.19 (4), p.277-298

LØNNING, Per E

2002

Volltextzugriff (PDF)

Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2–3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer

Annals of oncology, 2006-02, Vol.17 (2), p.217-225

Lønning, P.E.

2006

Volltextzugriff (PDF)

Influence of Droloxifene on Metastatic Breast Cancer as First-Line Endocrine Treatment

Acta oncologica, 1998, Vol.37 (4), p.365-368

Helge Haarstad, Per E. Lønning, Stein Gundersen, Erik Wist, Nils Raabe, Stener Kvinnsland

1998

Volltextzugriff (PDF)

Influence of Aromatase Inhibitors on Plasma Total Homocysteine in Postmenopausal Breast Cancer Patients

Clinical chemistry (Baltimore, Md.), 1999-02, Vol.45 (2), p.252-256

1999

Volltextzugriff (PDF)

Pharmacological and clinical profile of anastrozole

Breast cancer research and treatment, 1998-01, Vol.49 (S1), p.S53-S57

1998

Volltextzugriff (PDF)

Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients

Clinical cancer research, 1996-09, Vol.2 (9), p.1515-1521

1996

Volltextzugriff (PDF)

1 – 25 von 68

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

ThemaMedical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(62)

Publikationsform

Artikel
(68)

Sprache

Englisch
(68)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study

Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines

Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer

Impact of aromatase inhibitors on bone health in breast cancer patients

Recent data on intratumor estrogens in breast cancer

Alterations in the p53 Pathway and p16INK4a Expression Predict Overall Survival in Metastatic Melanoma Patients Treated with Dacarbazine

Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

Molecular portraits of human breast tumours

SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer

Aromatase inhibitors—Socioeconomical issues

Mutation of GATA3 in human breast tumors

Clinical pharmacokinetics of aromatase inhibitors and inactivators

High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy

Aromatase inhibitors as adjuvant treatment of breast cancer

Breast cancer prognostication and prediction: are we making progress?

Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer

Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique

Aromatase inhibitors—Socio-economical issues

Aromatase inhibitors and inactivators for breast cancer therapy

Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2–3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer

Influence of Droloxifene on Metastatic Breast Cancer as First-Line Endocrine Treatment

Influence of Aromatase Inhibitors on Plasma Total Homocysteine in Postmenopausal Breast Cancer Patients

Pharmacological and clinical profile of anastrozole

Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients

Aktive Filter

Suchergebnisse filtern